Corcept Therapeutics Inc
CORT
Market Cap$2.9B
Close$
$66.00
111.5% upside
Current Fair Value
111.5% upsideUndervalued by 111.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.90 Billion |
|---|---|
| Enterprise Value | $2.49 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $1.07 |
| Beta | 1.14 |
| Outstanding Shares | 104,110,000 |
| Avg 30 Day Volume | 1,136,482 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 24.56 |
|---|---|
| PEG | 32.82 |
| Price to Sales | 6.24 |
| Price to Book Ratio | 6.24 |
| Enterprise Value to Revenue | 4.75 |
| Enterprise Value to EBIT | 20.4 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Corcept Therapeutics Inc
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...